<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04246580</url>
  </required_header>
  <id_info>
    <org_study_id>GREEN-1</org_study_id>
    <nct_id>NCT04246580</nct_id>
  </id_info>
  <brief_title>Evaluation of Indocyanine Green-guided Systematic Pelvic Lymphadenectomy in Endometrial and Cervical Cancer</brief_title>
  <official_title>Evaluation of Indocyanine Green-guided Systematic Pelvic Lymphadenectomy in Endometrial and Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi dell'Insubria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi dell'Insubria</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The lymph nodes involvement is one of the most important prognostic factors in endometrial
      (EC) and cervical cancer (CC). Indeed, the lymph node involvement in cancer patients modifies
      the International Federation of Gynecology and Obstetrics (FIGO) stage and plays a pivotal
      role in the choice of the adjuvant therapy.

      Since the modern imaging techniques are not yet able to accurately detect lymph nodes
      metastasis, pelvic systematic lymphadenectomy has still an important role and it still
      represents the gold standard in EC and CC. The sentinel lymph node (SLN) biopsy, which is a
      standard practice in breast cancer and melanoma, is often used in some early stage
      gynaecological cancers such as EC and CC.

      Indocyanine green (ICG) is the most used tracer for the detection of SLN in gynaecological
      cancer, especially in laparoendoscopic setting. ICG allows a complete visualization of the
      lymphatic drainage and, for this reason, it may be used even in systematic pelvic
      lymphadenectomy to guide the surgeon during the procedure. Several studies have demonstrated
      an advantage of the ICG-guided lymphadenectomy in other types of cancers, showing a higher
      number of lymph nodes removed with this technique when compared to standard lymphadenectomy
      (without ICG).

      To date, there is no published study about ICG-guided systematic pelvic lymphadenectomy in EC
      and CC. In this scenario, the aim of this study will be to compare systematic ICG-guided
      pelvic lymphadenectomy and standard lymphadenectomy in EC and CC.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retrieved lymph nodes</measure>
    <time_frame>At the moment of the surgery</time_frame>
    <description>Number of retrieved lymph nodes after laparoscopic/robotic systematic pelvic lymphadenectomy</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Endometrial Cancer</condition>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Indocyanine green</arm_group_label>
    <description>Women with endometrial and cervical cancer undergoing indocyanine green-guided systematic pelvic lymphadenectomy by laparoscopy or robotic surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Women with endometrial and cervical cancer undergoing systematic pelvic lymphadenectomy by laparoscopy or robotic surgery without the use of indocyanine green tracer injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Indocyanine green-guided systematic pelvic lymphadenectomy</intervention_name>
    <description>Injection of Indocyanine green within the uterine cervix before to perform laparoscopic/robotic systematic pelvic lymphadenectomy</description>
    <arm_group_label>Indocyanine green</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women affected by endometrial or cervical cancer undergoing laparoscopic/robotic systematic
        pelvic lymphadenectomy (with or without previous injection of indocyanine green tracer
        within the uterine cervix).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women affected by endometrial or cervical cancer

          -  Laparoscopic/robotic surgical approach with systematic pelvic lymphadenectomy.

        Exclusion Criteria:

          -  Women undergoing open surgery (laparotomy) for the surgical management of endometrial
             or cervical cancer.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benito Chiofalo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regina Elena National Cancer Institute, Rome, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Simone Laganà, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Università degli Studi dell'Insubria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Simone Laganà, M.D., Ph.D.</last_name>
    <phone>+393296279579</phone>
    <email>antoniosimone.lagana@uninsubria.it</email>
  </overall_contact>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 26, 2020</study_first_submitted>
  <study_first_submitted_qc>January 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>January 26, 2020</last_update_submitted>
  <last_update_submitted_qc>January 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi dell'Insubria</investigator_affiliation>
    <investigator_full_name>Antonio Simone Laganà</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Indocyanine green</keyword>
  <keyword>Pelvic lymphadenectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

